Skip to main content
NCBI home page
Clinical and Experimental Immunology logoLink to Clinical and Experimental Immunology
. 1987 Nov;70(2):354–363.

Selective impairment of alpha-interferon-mediated natural killer augmentation in Sjögren's syndrome: differential effects of alpha-interferon, gamma-interferon, and interleukin 2 on cytolytic activity.

A Takeda 1, N Minato 1, S Kano 1
PMCID: PMC1542081  PMID: 2448073

Abstract

Natural killer (NK) function has been shown to be impaired in several autoimmune diseases including Sjögren's syndrome (SS). In the present study, in vitro effects of alpha-interferon (alpha-IFN), gamma-IFN and interleukin 2 (IL-2) on the NK cell activity were examined to analyse the regulatory system of NK-augmentation in patients with SS. The responsiveness of NK cell activity to alpha-IFN was markedly depressed in SS patients compared with normal controls, whereas the responsiveness to gamma-IFN was within normal limits. This is the first demonstration of the selective hyporesponsiveness of NK cell activity to one type of IFN in a certain disease. In addition, the kinetics study of NK-augmentation in normal donors revealed that alpha-IFN enhanced NK cell activity with a faster profile than gamma-IFN. These findings imply substantial differences between the two types of IFN in their mechanisms for enhancing NK cell activity, which deserve attention in evaluating the effects of IFNs. The present study also demonstrated that IL-2 could induce significantly higher levels of NK cell activity than alpha-IFN or gamma-IFN in SS and that this enhancing effect was almost comparable to that in normal controls. Thus, there seem to be multiple regulatory mechanisms for enhancement of NK cell activity, and a portion of the mechanisms may be selectively impaired in certain human diseases such as SS. The selective hyporesponsiveness to alpha-IFN could be relevant to the idea of viral participation in pathogenesis of SS.

Full text

PDF
354

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anderson P., Yip Y. K., Vilcek J. Specific binding of 125I-human interferon-gamma to high affinity receptors on human fibroblasts. J Biol Chem. 1982 Oct 10;257(19):11301–11304. [PubMed] [Google Scholar]
  2. BLOCH K. J., BUCHANAN W. W., WOHL M. J., BUNIM J. J. SJOEGREN'S SYNDROME. A CLINICAL, PATHOLOGICAL, AND SEROLOGICAL STUDY OF SIXTY-TWO CASES. Medicine (Baltimore) 1965 May;44:187–231. [PubMed] [Google Scholar]
  3. Baglioni C., Maroney P. A. Mechanisms of action of human interferons. Induction of 2'5'-oligo(A) polymerase. J Biol Chem. 1980 Sep 25;255(18):8390–8393. [PubMed] [Google Scholar]
  4. Branca A. A., Baglioni C. Down-regulation of the interferon receptor. J Biol Chem. 1982 Nov 25;257(22):13197–13200. [PubMed] [Google Scholar]
  5. Branca A. A., Baglioni C. Evidence that types I and II interferons have different receptors. Nature. 1981 Dec 24;294(5843):768–770. doi: 10.1038/294768a0. [DOI] [PubMed] [Google Scholar]
  6. Böyum A. Isolation of leucocytes from human blood. Further observations. Methylcellulose, dextran, and ficoll as erythrocyteaggregating agents. Scand J Clin Lab Invest Suppl. 1968;97:31–50. [PubMed] [Google Scholar]
  7. Claeys H., Van Damme J., De Ley M., Vermylen C., Billiau A. Activation of natural cytotoxicity of human peripheral blood mononuclear cells by interferon: a kinetic study and comparison of different interferon types. Br J Haematol. 1982 Jan;50(1):85–94. doi: 10.1111/j.1365-2141.1982.tb01893.x. [DOI] [PubMed] [Google Scholar]
  8. Devos R., Cheroutre H., Taya Y., Degrave W., Van Heuverswyn H., Fiers W. Molecular cloning of human immune interferon cDNA and its expression in eukaryotic cells. Nucleic Acids Res. 1982 Apr 24;10(8):2487–2501. doi: 10.1093/nar/10.8.2487. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Dianzani F., Salter L., Fleischmann W. R., Jr, Zucca M. Immune interferon activates cells more slowly than does virus-induced interferon. Proc Soc Exp Biol Med. 1978 Oct;159(1):94–97. doi: 10.3181/00379727-159-40291. [DOI] [PubMed] [Google Scholar]
  10. Fox R. I., Pearson G., Vaughan J. H. Detection of Epstein-Barr virus-associated antigens and DNA in salivary gland biopsies from patients with Sjogren's syndrome. J Immunol. 1986 Nov 15;137(10):3162–3168. [PubMed] [Google Scholar]
  11. Goeddel D. V., Yelverton E., Ullrich A., Heyneker H. L., Miozzari G., Holmes W., Seeburg P. H., Dull T., May L., Stebbing N. Human leukocyte interferon produced by E. coli is biologically active. Nature. 1980 Oct 2;287(5781):411–416. doi: 10.1038/287411a0. [DOI] [PubMed] [Google Scholar]
  12. Grundy J. E., Trapman J., Allan J. E., Shellam G. R., Melief C. J. Evidence for a protective role of interferon in resistance to murine cytomegalovirus and its control by non-H-2-linked genes. Infect Immun. 1982 Jul;37(1):143–150. doi: 10.1128/iai.37.1.143-150.1982. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Herberman R. R., Ortaldo J. R., Bonnard G. D. Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity. Nature. 1979 Jan 18;277(5693):221–223. doi: 10.1038/277221a0. [DOI] [PubMed] [Google Scholar]
  14. Kassan S. S., Thomas T. L., Moutsopoulos H. M., Hoover R., Kimberly R. P., Budman D. R., Costa J., Decker J. L., Chused T. M. Increased risk of lymphoma in sicca syndrome. Ann Intern Med. 1978 Dec;89(6):888–892. doi: 10.7326/0003-4819-89-6-888. [DOI] [PubMed] [Google Scholar]
  15. Liang S. M., Allet B., Rose K., Hirschi M., Liang C. M., Thatcher D. R. Characterization of human interleukin 2 derived from Escherichia coli. Biochem J. 1985 Jul 15;229(2):429–439. doi: 10.1042/bj2290429. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Minato N., Takeda A., Kano S., Takaku F. Studies of the function of natural killer-interferon system in patients with Sjögren syndrome. J Clin Invest. 1982 Mar;69(3):581–588. doi: 10.1172/JCI110484. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Quinnan G. V., Manischewitz J. E. The role of natural killer cells and antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection. J Exp Med. 1979 Dec 1;150(6):1549–1554. doi: 10.1084/jem.150.6.1549. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sayers T. J., Mason A. T., Ortaldo J. R. Regulation of human natural killer cell activity by interferon-gamma: lack of a role in interleukin 2-mediated augmentation. J Immunol. 1986 Mar 15;136(6):2176–2180. [PubMed] [Google Scholar]
  19. Schwartz R. S., André-Schwartz J. Malignant lymphoproliferative diseases: interactions between immunological abnormalities and oncogenic viruses. Annu Rev Med. 1968;19:269–282. doi: 10.1146/annurev.me.19.020168.001413. [DOI] [PubMed] [Google Scholar]
  20. Senik A., Stefanos S., Kolb J. P., Lucero M., Falcoff E. Enhancement of mouse natural killer cell activity by type II interferon. Ann Immunol (Paris) 1980 May-Jun;131C(3):349–361. [PubMed] [Google Scholar]
  21. Shillitoe E. J., Daniels T. E., Whitcher J. P., Vibeke Strand C., Talal N., Greenspan J. S. Antibody to cytomegalovirus in patients with Sjögren's syndrome. As determined by an enzyme-linked immunosorbent assay. Arthritis Rheum. 1982 Mar;25(3):260–265. doi: 10.1002/art.1780250303. [DOI] [PubMed] [Google Scholar]
  22. Sibbitt W. L., Jr, Gibbs D. L., Kenny C., Bankhurst A. D., Searles R. P., Ley K. D. Relationship between circulating interferon and anti-interferon antibodies and impaired natural killer cell activity in systemic lupus erythematosus. Arthritis Rheum. 1985 Jun;28(6):624–629. doi: 10.1002/art.1780280605. [DOI] [PubMed] [Google Scholar]
  23. Strand V., Talal N. Advances in the diagnosis and concept of Sjögren's syndrome (autoimmune exocrinopathy). Bull Rheum Dis. 1979;30(9):1046–1052. [PubMed] [Google Scholar]
  24. Svedersky L. P., Shepard H. M., Spencer S. A., Shalaby M. R., Palladino M. A. Augmentation of human natural cell-mediated cytotoxicity by recombinant human interleukin 2. J Immunol. 1984 Aug;133(2):714–718. [PubMed] [Google Scholar]
  25. TALAL N., BUNIM J. J. THE DEVELOPMENT OF MALIGNANT LYMPHOMA IN THE COURSE OF SJOEGREN'S SYNDROME. Am J Med. 1964 Apr;36:529–540. doi: 10.1016/0002-9343(64)90101-9. [DOI] [PubMed] [Google Scholar]
  26. Trinchieri G., Matsumoto-Kobayashi M., Clark S. C., Seehra J., London L., Perussia B. Response of resting human peripheral blood natural killer cells to interleukin 2. J Exp Med. 1984 Oct 1;160(4):1147–1169. doi: 10.1084/jem.160.4.1147. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. de Ley M., van Damme J., Claeys H., Weening H., Heine J. W., Billiau A., Vermylen C., de Somer P. Interferon induced in human leukocytes by mitogens: production, partial purification and characterization. Eur J Immunol. 1980 Nov;10(11):877–883. doi: 10.1002/eji.1830101113. [DOI] [PubMed] [Google Scholar]
  28. van de Griend R. J., Ronteltap C. P., Gravekamp C., Monnikendam D., Bolhuis R. L. Interferon-beta and recombinant IL 2 can both enhance, but by different pathways, the nonspecific cytolytic potential of T3- natural killer cell-derived clones rather than that of T3+ clones. J Immunol. 1986 Mar 1;136(5):1700–1707. [PubMed] [Google Scholar]

Articles from Clinical and Experimental Immunology are provided here courtesy of British Society for Immunology

RESOURCES